Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Aringazina R.A. Zare A. Mousavi S.M. Abenova N. Mussin N.M. Tamadon A.
26 July 2025Baishideng Publishing Group Inc
World Journal of Stem Cells
2025#17Issue 71 - 17 pp.
BACKGROUND Diabetes mellitus (DM) is a global health concern, characterized by insulin resistance and β-cell dysfunction. Traditional treatments often fail to address underlying mechanisms, necessitating alternative therapies. Mesenchymal stem cell (MSC)-based therapies have shown promise due to their regenerative and immunomodulatory properties. However, evidence on their efficacy and safety in type 2 DM remains limited and further evaluation is needed. AIM To evaluate the safety, efficacy and therapeutic potential of MSC-based therapies in type 2 DM. METHODS This systematic review analyzed studies published between 2000 and 2025, focusing on autologous and allogeneic MSC therapies in DM. Studies were identi fied from various databases, including clinical and preclinical trials. Outcomes related to glycemic control, insulin requirements, β-cell function, and safety were assessed. RESULTS MSC-based therapies significantly improved glycemic control, reduced insulin requirements and enhanced β-cell function in both clinical and preclinical settings. Safety profiles were favorable, with minimal adverse effects observed, primarily transient and self-limiting. No fatal events were reported. Variability in treatment outcomes and the need for standardized protocols were challenges. CONCLUSION MSC-based therapies offer a promising alternative to conventional DM treatments, significantly improving glycemic control and safety. Further research is needed to refine protocols and confirm long-term efficacy.
Cell therapy , Insulin lessen , Insulin resistance , Mesenchymal stem cell , Metabolic disorders , Obesity , Type 2 diabetes mellitus
Text of the article Перейти на текст статьи
Department of Internal Medicine No. 2, West Kazakhstan Marat Ospanov Medical University, Aktobe, 030019, Kazakhstan
Drug Discovery and Development Industry, School of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan
Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 106335, Taiwan
Department of Family Medicine No. 2, West Kazakhstan Marat Ospanov Medical University, Aktobe, 030019, Kazakhstan
Department of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, 030019, Kazakhstan
Department of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, 030012, Kazakhstan
Department of Internal Medicine No. 2
Drug Discovery and Development Industry
Department of Chemical Engineering
Department of Family Medicine No. 2
Department of General Surgery
Department of Natural Sciences
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026